0001171843-14-005935.txt : 20141217 0001171843-14-005935.hdr.sgml : 20141217 20141217163040 ACCESSION NUMBER: 0001171843-14-005935 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141216 ITEM INFORMATION: Other Events FILED AS OF DATE: 20141217 DATE AS OF CHANGE: 20141217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 141292916 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 8-K 1 f8k_121714.htm FORM 8-K f8k_121714.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of report (Date of earliest event reported): December 16, 2014
 
Immunomedics, Inc.
(Exact Name of Registrant as Specified in Charter)

 Delaware 000-12104 61-1009366
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

300 The American Road, Morris Plains, New Jersey 07950
(Address of Principal Executive Offices)
(Zip Code)

(973) 605-8200
(Registrant's telephone number,
including area code)
 
 
___________________Not applicable_____________________
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
 
 
 
 
Item 8.01.    Other Events
 
On October 3, 2013, Takeda Pharmaceutical Company Limited, the parent company of Nycomed GmbH (“Takeda-Nycomed”), delivered notice of termination of its worldwide licensing agreement (the “Agreement”) with Immunomedics, Inc. (the “Company”) to develop, manufacture and commercialize veltuzumab for the treatment of all non-cancer indications.  Takeda-Nycomed terminated the Agreement subsequent to the Company’s filing of arbitration proceedings concerning delays in Takeda-Nycomed’s development of veltuzumab, which the Company argued was a material breach of the Agreement.  In response to the Company’s claim for damages for the delays, Takeda-Nycomed made certain counterclaims against the Company.

On December 16, 2014, the Company was notified that the arbitrator awarded no money to either party and the award was in full settlement of all claims and counterclaims submitted to arbitration.  All rights to veltuzumab have reverted back to the Company as a result of the termination.
 
 
 

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    IMMUNOMEDICS, INC.
   
 
 
 
    By: /s/ Cynthia L. Sullivan
      Name: Cynthia L. Sullivan
      Title: President and Chief Executive Officer
 
 
Date:  December 17, 2014